The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Kennedy Jr. purged the nation’s most important panel of vaccine experts: All 17 voting members of the CDC’s Advisory Committee on Immunization ... who has embraced the “anti-vaccine” label and ...

If I have sounded like a broken record these past months, it is because these developments in American public health are as ...

The CDC director typically signs off on the panel's recommendations before they are implemented, but the agency does not currently have one.

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s Enflonsia.

The CDC's vaccine advisory committee said it will study the childhood immunization schedule in the first meeting featuring HHS Secretary RFK Jr.'s hand-selected members.

The CDC plans to publish clinical considerations that outline the chronic medical conditions and other risk factors for severe RSV disease to be used under this recommendation.

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory panel. Read more here.

The CDC's vaccine advisory committee voted on Thursday to recommend infants receive a newer monoclonal antibody shot for respiratory syncytial virus.